Kiadis Pharma N.V., a clinical stage biopharmaceutical company, engages in the pharmaceutical development of cell-based immunotherapy products in the field of blood building system diseases.
The last earnings update was 236 days ago.
Discounted Cash Flow Calculation for DB:K3P using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:K3P DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Kiadis Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
Kiadis Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Kiadis Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Kiadis Pharma's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Kiadis Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Kiadis Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Arthur Lahr has been Chief Executive Officer of Kiadis Pharma N.V. since April 01, 2017 and served as its Chief Operating Officer from January 1, 2017 to April 01, 2017. Mr. Lahr served as Chief Executive Officer of FastTrack Company. Mr. Lahr served as the Head of the Protein Business Unit at Crucell N.V. since July 18, 2007 and served as its Chief Strategy Officer. Mr. Lahr served as Executive Vice President of Business Development of Crucell N.V. since January 2004 and served as its Executive Vice President of Sales. Mr. Lahr serves as Member of the Management board of Kiadis Pharma N.V. He served as Vice President of Business Development of Crucell N.V since December 2003, as Executive Vice President since January 2006 and assumed responsibility for European marketing, sales and strategy in 2006. Mr. Lahr joined Crucell N.V in April 2001 as an Executive Director of Business Development. From 1994 to 2001, he served as a Consultant of McKinsey & Co. in The Netherlands and New York. Prior to that, he worked with Unilever. He served as Member of the Governance Board at Percivia LLC. Mr. Lahr holds a Masters in Business Administration from INSEAD and a Masters in Science in Applied Physics from the University of Delft, the Netherlands.
Insufficient data for Arthur to compare compensation growth.
Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Kiadis Pharma management team is less than 2 years, this suggests a new team.
CEO & Member of the Management Board
Chief Financial Officer
Chief Operating Officer
Chief Scientific Officer
General Counsel & Company Secretary
Head of Corporate Development
Chief Human Resources Officer
Chief Medical Officer
Dirk De Naeyer
Head of Supply Chain
Head of Commercial Europe
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Kiadis Pharma board of directors is about average.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, engages in the pharmaceutical development of cell-based immunotherapy products in the field of blood building system diseases. Its lead product candidate is ATIR101 that is in Phase III clinical trials to address key risks and limitations of hematopoietic stem cell transplantation for adult blood cancers. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.